Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BsUFA III Expands Biosimilar Supplement Review Goals To Speed Approvals

Sep 22 2021

• By Derrick Gingery

FDAEntrance_1200x675 — The FDA plans to hire an additional 15 employees to help implement the BsUFA III program changes.

Related Content

Biosimilars Will Get Regulatory Science Program, Supplement Timeline Changes In Next User Fee Agreement

Jul 13 2021

US FDA Rebates Biosimilar Fees, Limits Generic Fee Hike In FY 2022

Jul 27 2021

PDUFA VII Commitment Letter Outlines Real-Time Review Expansion, Hiring Goals

Aug 23 2021

Two Months To Add Two Words – Biosimilar Supplement Review Times May Be Hindering Uptake

May 01 2019

Additional Topics

United States User Fees Biosimilars Regulation FDA Review Pathway BioPharmaceutical

More from User Fees

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window